Publication date: Aug 01, 2024
Current standard treatment for metastatic breast cancer (MBC) involves cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy, showing potential in enhancing anti-tumor immune responses. This report details a clinical case of MBC where palbociclib was co-administered with letrozole. The integration of allogeneic tumor vaccination to this treatment led to heightened interferon-γ production, expansion of CD8+ and NK cell populations, and positive delayed-type hypersensitivity reactions, indicating successful development of anti-tumor immunity. The induced production of interferon-γ by tumor vaccination was associated with manageable modulation of sensitivity to palbociclib-letrozole therapy. Administration of the BioNTech/Pfizer Covid-19 vaccine compromised the anti-tumor immune response by reducing cytotoxic cell populations and increasing immunosuppressive cytokine production. The patient undergoing combined treatment achieved a progressive-free survival of 42 months. Incorporating active tumor vaccination with CDK4/6 inhibitor therapy presents a feasible approach for metastatic breast cancer. The precise regulation of the microenvironment emerges as a crucial factor and warrants careful consideration.
| Concepts | Keywords |
|---|---|
| Biontech | cancer vaccination |
| Cancer | CDK4/6 inhibitors |
| Cdk4 | COVID-19 vaccination |
| Manageable | cytokines |
| Vaccination | Metastatic breast cancer |
| thymidine kinase 1 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Tumor |
| disease | VO | vaccination |
| disease | VO | report |
| disease | MESH | breast cancer |
| pathway | KEGG | Breast cancer |
| drug | DRUGBANK | Palbociclib |
| drug | DRUGBANK | Letrozole |
| disease | IDO | production |
| disease | IDO | cell |
| disease | VO | COVID-19 vaccine |
| disease | IDO | immune response |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Deoxythymidine |